Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GDC-0919 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| GDC-0919 Dose Escalation | EXPERIMENTAL | GDC-0919 to be given on an outpatient basis as a single agent. Starting dose of GDC-0919 will be 50 mg by mouth every 12 hour. Patients will receive the study drug daily for 21 days followed by 7 days off for a cycle length of 28 days; or on 28 consecutive days of a 28-day cycle |
| Name | Type | Description |
|---|---|---|
| GDC-0919 | DRUG | Supplied in 50 mg and 200 mg capsules. To be taken every 12 hours with water by mouth on an empty stomach (no food or drink other than water for 2 hours prior to dose). Taken twice daily for 21 days each cycle, followed by 7 days off; or taken twice daily on 28 consecutive days of a 28-day cycle |
Inclusion Criteria: * Histologically or cytologically confirmed solid tumor that is relapsed/refractory to standard therapies or for which no approved or curative therapy exists * Age \> or = 18 * Eastern Cooperative Oncology Group (ECOG) performance status \< 2 * Life expectancy \> or = 12 weeks *...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
GDC-0919 is an investigational small molecule being studied for the treatment of solid tumors. It is in Phase 1 clinical development for oncology indications. The drug is not yet approved and remains under investigation in clinical trials.
GDC-0919 is an indoleamine 2,3-dioxygenase (IDO) inhibitor. It is being studied in advanced solid tumors as part of a Phase 1 clinical trial. The drug targets the IDO pathway, which is involved in immune regulation in the tumor microenvironment.
GDC-0919 is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker symbol RHHBY. The drug is currently in Phase 1 clinical development for solid tumors.
GDC-0919 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of solid tumors in an early-stage clinical trial.
GDC-0919 has been studied in one clinical trial, identified as NCT02048709, titled 'Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors.' This Phase 1 trial was completed and enrolled 22 participants in the United States.
Yes, GDC-0919 is an indoleamine 2,3-dioxygenase (IDO) inhibitor. It is being investigated for its potential role in treating solid tumors by targeting the IDO pathway. The drug is currently in Phase 1 clinical development.